Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant

Donato Rigante, Luca Cantarini, Giuseppe Lopalco, Antonio Vitale, Francesco Caso, Giovanni Lapadula, Florenzo Iannone, Mauro Galeazzi

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

6 Citazioni (Scopus)

Abstract

The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript.
Lingua originaleEnglish
pagine (da-a)473-475
Numero di pagine3
RivistaInternational Journal of Rheumatic Diseases
Volume2015
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Autoinflammation

Fingerprint

Entra nei temi di ricerca di 'Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant'. Insieme formano una fingerprint unica.

Cita questo